Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)
Takeda Will Make an Upfront Payment of $300 Million at Closing
Partnership Combines Protagonist's Leadership in Pharmaceutical Peptide Drug Development With Takeda's Commercial Expertise and 70-Plus Year Legacy of Driving Innovation Within the Rare Hematology Community
Protagonist to Host Conference Call and Webcast Today at 4:30 PM ET
Protagonist management will host a conference call and webcast today at 4:30 p.m. ET to provide a brief overview of the co-commercialization agreement.
Wednesday, January 31 at 4:30 PM ET
Domestic: (877) 704-4390 (U.S./Canada)
International: (201) 389-0920
Conference ID: 13744228
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.
Call me™:
https://callme.viavid.com/viavid/?callme=true&passcode=13744228&h=true&info=company-email&r=true&B=6
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1654841&tp_key=6b0a844538
A live and archived webcast will also be accessible in the Investors section of the Company's website at www.protagonist-inc.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.